Lead researcher talks about remdesivir clinical trials
The COVID-19 Infectious Disease team at University Health and UT Health San Antonio is participating in the patient testing of a promising COVID-19 drug, remdesivir. Based on encouraging, preliminary results, the U.S. Food and Drug Administration authorized emergency use of the antiviral medication.
Dr. Thomas Patterson, professor and chief of the Division of Infectious Diseases at UT Health San Antonio, is leading the study at University Hospital. In this interview he talks about what researchers have learned so far and their hopes for an effective treatment. We asked him these key questions:
- What is remdesivir and how does it affect the COVID-19 virus?
- What resulted from the first phase of the clinical trial?
- What happens in the second phase of the remdesivir clinical trial?
- What COVID-19 treatment could result from this research?
Check out the news section of our University Health website for more information on the first and second phase of our remdesivir study.
